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ARTICLE
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1Department

West Nile virus (WNV) causes a severe infection of the central nervous system in several
vertebrate animals including humans. Prior studies have shown that complement plays a
critical role in controlling WNV infection in complement (C) 3−/− and complement receptor
1/2−/− mice. Here, we dissect the contributions of the individual complement activation
pathways to the protection from WNV disease. Genetic deficiencies in C1q, C4, factor B, or
factor D all resulted in increased mortality in mice, suggesting that all activation pathways
function together to limit WNV spread. In the absence of alternative pathway complement
activation, WNV disseminated into the central nervous system at earlier times and was
associated with reduced CD8+ T cell responses yet near normal anti-WNV antibody profiles.
Animals lacking the classical and lectin pathways had deficits in both B and T cell responses
to WNV. Finally, and somewhat surprisingly, C1q was required for productive infection in
the spleen but not for development of adaptive immune responses after WNV infection.
Our results suggest that individual pathways of complement activation control WNV infection by priming adaptive immune responses through distinct mechanisms.
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Abbreviations used: C, complement; CNS, central nervous
system; CR, complement
receptor; E, envelope; fB, factor
B; fD, factor D; LCMV, lymphocytic choriomeningits virus;
MBL, mannose binding lectin;
WNV, West Nile virus.

The complement system is a family of more
than 30 proteins and cell surface receptors that
recognize pathogen-associated molecular patterns, altered-self ligands, or immune complexes. Complement activation through the
classical, lectin, and alternative pathways induces
several protective functions including direct
pathogen opsonization and/or lysis, and enhancement of B and T responses (1). Through
these innate and adaptive responses complement
contributes to the development of immunity
against some enveloped DNA and RNA viruses
(2–5). Several of these viruses have been shown
to trigger distinct pathways of complement activation in vitro. Glycoproteins of murine leukemia, HIV, and human T cell lymphotropic
viruses directly interact with C1q to activate the
classical pathway (6). Carbohydrates on the
structural proteins of HSV, hepatitis B, and influenza viruses bind mannose binding lectins
(MBLs) and activate the lectin pathway (7, 8).
Multiple viruses activate the alternative pathway, including Sindbis (9), Sendai (10), measles
(11, 12), and Epstein Barr viruses (13). However, the in vivo contribution of each complement activation pathway to the development of
antiviral immunity has yet to be defined.
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West Nile encephalitis virus (WNV) is a
single-stranded positive sense RNA virus of
the Flaviviridae family. WNV cycles in nature
between mosquitoes and birds, but also infects
human, horses, and other vertebrates. The virus
is endemic in parts of Africa, Asia, Europe, and
the Middle East, and has become established in
North America. Infected humans generally develop a febrile illness, with a subset progressing
to severe neurological disease. The elderly and
patients with impaired immune systems are at
greatest risk for the severe neurological manifestations of disease. Experiments in mice have
begun to elucidate how an impaired host immune response results in severe WNV infection. An intact innate and adaptive immune
response is required to limit central nervous
system (CNS) infection as mice deficient in
type I IFN, γδ T cells, B cells, soluble IgM,
and CD8+ T cells are all highly susceptible to
lethal infection (14–19). Additionally, complement is required to control WNV, as mice
deficient in either complement (C)3 or complement receptor (CR)1/2 were vulnerable to
lethal WNV infection (20).
In this study, we investigated the activation requirements for complement-mediated
1371

control of WNV dissemination and disease. We observed a
marked increased in WNV susceptibility in mice deficient in
any of the pathways of complement activation. However, the
virologic and immunologic phenotypes of the various complement-deficient mice were distinct, suggesting that the
concerted activation of the classical, lectin, and alternative
pathways is required to fully prime adaptive immune responses and control WNV infection.
RESULTS
Complement activation in vivo after WNV infection
Previous studies have suggested that other pathogenic flaviviruses, such as Dengue virus, activate complement leading
to consumption of complement proteins and more severe
disease (21, 22). To confirm that complement activation occurs in vivo after WNV infection, we compared the levels of
functional C3 and C4 in the serum of naive and WNVinfected C57BL/6 mice using an erythrocyte hemolysis assay
(Fig. 1 A). On day 2 after WNV infection, a time point at
which peak viremia was observed (see Fig. 3 A), a 2.5-fold
decrease in C3 functional activity (P < 0.0001) was measured.
Significant decreases, albeit smaller, were also noted on days
4 and 6 after infection (P ≤ 0.02). C4 activity (23) was also
reduced at day 2 after WNV infection (Fig. 1 B). As the
catabolism of C3 in vivo generates a C3dg fragment, Western
blot analysis was performed on serum from WNV-infected
mice with an anti-C3 antibody. Increased levels of the 38-kD
C3dg fragment were observed in serum at day 2 after WNV
infection (Fig. 1 C); the identity of this fragment was
confirmed by its absence from serum of congenic C3deficient mice. Collectively, our experiments suggest that
WNV infection activates and consumes complement within
days of infection.
Susceptibility of complement-deficient mice
to WNV infection
To assess the mechanism of complement-mediated protection from WNV disease and the function of the classical, classical and lectin, or alternative pathways of complement
activation in control of WNV, we evaluated morbidity and
mortality in wild-type and congenic C1q−/−, C4−/−, factor D
(fD)−/−, and factor B (fB)−/− C57BL/6 mice. Mice in all
groups exhibited clinical signs of infection including weight
loss, hunching, fur ruffling, and decreased activity. However,
mice deficient in any individual complement activation pathway were more vulnerable to infection and had higher mortality rates compared with wild-type mice (Fig. 2). Whereas
only 35% of wild-type C57BL/6 mice succumbed to infection, 83% of C1q−/− (n = 60, P < 0.0001), 100% of C4−/−
(n = 38, P < 0.0001), 74% of fD−/−, (n = 57, P = 0.0004),
and 96% of fB−/− (n = 51, P < 0.0001) mice died after
WNV infection (Fig. 2). Not all complement deficiencies
were associated with enhanced susceptibility as infection of
mice deficient in the C5a receptor (C5aR) survived at rates
similar to wild-type mice (n = 50, P = 0.5). Although both
fB and fD are components of the alternative pathway, a defi1372

Figure 1. Complement is activated in vivo in response to WNV
infection. Levels of functional (A) C3 and (B) C4 were determined by
erythrocyte hemolysis assay of serum samples from naive and WNVinfected mice. Differences in the C3 and C4 activity between naive and
WNV-infected mice were statistically significant (P < 0.05). (C) Serum
complement activation was evaluated by Western blot using equal volumes of serum (20 μl of 1/50 dilution) from naive wild-type and C3−/−
mice and WNV-infected (day 2) wild-type mice. Bands corresponding to
the C3 α chain (100 kD), C3 β chain (75 kD), and C3dg (38 kD) are labeled.

ciency of fB caused greater mortality after WNV infection
(P < 0.0001), possibly caused by residual alternative pathway
activation in fD−/− mice (24). Overall, the C4−/− and fB−/−
mice were more susceptible to lethal WNV infection than
either C1q−/− or fD−/− mice (P < 0.0001). The increased
susceptibility of fB−/− mice was also reflected by a decrease
in the mean time to death from 10.9 ± 0.3 d for wild-type
mice to 9.7 ± 0.1 d for the fB−/− mice (P = 0.002). No statistically significant decrease in the mean time to death was
observed for C4−/− (10.3 ± 0.2 d), C1q−/− (11.7 ± 0.2 d),
or fD−/− (11.0 ± 0.2 d) mice. Thus, deficiencies in all complement activation pathways resulted in increased mortality
after WNV infection. The most severe phenotypes were observed in mice that had a combined deficiency in the classical
and lectin pathways (C4−/−) or a complete deficiency in the
alternative pathway (fB−/−).
WNV tissue burden in complement-deficient mice
To elucidate the mechanisms by which deficiencies in complement activation pathways enhanced susceptibility to WNV
infection, a kinetic analysis of viral burden was performed
(Fig. 3 and 4). Wild-type and complement-deficient C57BL/6
COMPLEMENT PATHWAY CONTROL OF WNV INFECTION | Mehlhop and Diamond
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Spleen and lymph node. Previous experiments have
shown that a deficiency of C3 results in a delayed clearance

of WNV from the spleen (20). To assess which complement
pathway contributed to viral clearance in the spleen, we evaluated WNV burden in C1q−/−, C4−/−, fD−/−, and fB−/−
mice (Fig. 3 B). Compared with wild-type mice, we observed a slight delay in clearance of WNV from the spleen in
a subset of fD−/− and fB−/− mice. At day 6 after infection,
58% (7 of 12) and 73% (11 of 15) of fD−/− and fB−/− mice,
respectively, had detectable infectious WNV in the spleen,
whereas only 33% (5 of 15) of wild-type mice had infectious
virus at this time point. On day 8 after infection 57% (8 of 14)
of fB−/− mice still had measurable infectious virus in the
spleen, whereas it was no longer detectable in wild-type
mice. Surprisingly, infectious virus was never recovered from
the spleens of C1q−/− mice at any point during the time
course (n ≥ 11 for each time point). Consistent with this, at
the peak of viral replication in the spleen, 120,000-fold lower
levels of WNV RNA were detected by quantitative RTPCR from the spleens of C1q−/− mice compared with wildtype mice (Fig. 3 C, P = 0.002). The peak viral burden and
number of positive samples in the spleen also was significantly
lower in the absence of C4 (P = 0.04). Whereas 80% (12 of 15)
of wild-type spleen samples were positive for infectious virus
at day 4 after infection, only 30% (4 of 12) from C4−/− mice
had infectious virus. Moreover, on day 6 after infection
60,000-fold lower levels of WNV RNA were detected in
spleens of C4−/− mice (P = 0.001). Thus, in the spleen, classical pathway activation appears to be necessary for productive infection, whereas the alternative pathway contributes in
part to its rapid clearance of WNV.
Decreased WNV burden in spleens of C1q−/− and C4−/−
mice was not predicted. Previous studies in mice indicated
that F4/80+ macrophages and CD19+ B cells were the principal cellular targets for WNV infection in the spleen (18).
Because infection of C1q−/− mice resulted in normal viremia, we hypothesized that virus must replicate in another
peripheral tissue. Studies from our group and others (14, 26)
indicate that draining lymph nodes are an early site of WNV
replication. To determine one possible source of viremia in

Figure 3. WNV infection in serum and lymphoid tissues. WNV RNA
levels in the serum (A), spleen (C), and draining inguinal lymph node (D)
of wild-type, C1q−/−, C4−/−, fD−/−, and fB−/− mice at the indicated days
were determined by quantitative RT-PCR from at least 4–6 independent
mice per time point per group. Infectious WNV burden in the spleen (B) of

wild-type, C1q−/−, C4−/−, fD−/−, and fB−/− mice at the indicated days was
determined by plaque assay of samples from 8–15 mice per time point
per group. The dotted line indicates the limit of sensitivity of the assay.
Asterisks indicate time points at which differences are statistically significant compared with wild type.

Figure 2. All pathways of complement activation are required for
survival of WNV infection. Wild-type (n = 95), C1q−/− (n = 60), C4−/−
(n = 34), fD−/− (n = 57), fB−/− (n = 50), and C5aR−/− (n = 50) C57BL/6
mice were infected with 102 PFU by footpad injection in at least three
independent experiments. Significant decreases in survival as compared
with wild-type mice were noted for all complement deficient mice
(P ≤ 0.0004), except C5aR−/− mice (P = 0.5).

mice were infected with WNV, and viral loads in the serum,
spleen, inguinal lymph node, spinal cord, and brain were determined on days 2, 4, 6, 8, and 10 after infection.
Viremia. Throughout the time course of infection, viremia
was below the limit of detection by direct plaque assay in all
samples (unpublished data). However, when viral RNA was
measured by quantitative RT-PCR assay (25), additional information was obtained. In wild-type mice, viremia peaked
at day 2 after infection and decreased over the next several
days. No significant difference in viremia was observed at any
time point after infection in C1q−/−, fB−/−, or fD−/− mice
(Fig. 3 A, P ≥ 0.5). The only variation among complementdeficient mice occurred in C4−/− mice, which had slightly
higher WNV RNA levels than wild-type mice (n = 8, P =
0.009), but only on day 4 after infection.
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Figure 4. WNV infection in CNS tissues. Infectious WNV burden in
(A) spinal cord and (C) brain from wild-type, C1q−/−, C4−/−, fD−/−, and fB−/−
mice was determined by plaque assay of samples from 8–15 mice per time

point per group. Scatter plots of (B) spinal cord and (D) brain titers from
individual mice at day 4 or 10 are shown to the right of each graph. The limit
of sensitivity of the assay and statistical significance are as described in Fig 3.

the C1q−/− and C4−/− animals, viral burden in the inguinal
lymph nodes was measured by quantitative RT-PCR (Fig. 3 D).
Equivalent levels of WNV RNA were detected on the first
and second days after infection in wild-type, C1q−/−, and
C4−/− mice (P ≥ 0.8). However, by 3 d after infection fourfold less WNV RNA was found in the draining inguinal
lymph nodes of C1q (P = 0.05) and C4−/− mice (P = 0.04)
compared with wild-type mice.

Viral burden in the brain peaked in wild-type mice on day 8
after infection. In contrast, levels of infectious WNV continued to rise in C1q−/−, C4−/−, fD−/−, and fB−/− mice such
that 10–200-fold higher levels were observed by day 10 after
infection (P ≤ 0.04). The analysis of viral burden in the CNS
suggests that a deficiency in primarily the alternative pathway
results in earlier WNV entry and accumulation, whereas a
deficiency in any of the complement pathways results in increased viral load.

CNS: spinal cord. Distinct patterns of WNV invasion and
accumulation in the spinal cord were observed in C1q−/−,
C4−/−, fD−/−, and fB−/− mice (Fig. 4 A). In agreement with
published studies, WNV was not detected in spinal cord samples from wild-type mice until day 8 after infection (16).
Similarly, infectious virus was not recovered from the spinal
cords of C1q−/− or fD−/− mice until day 8 after infection.
In the absence of either fB or C4, however, WNV was detected in a subset of spinal cord samples 2 d earlier. At day 6,
47% (7 of 15) fB−/− and 50% (6 of 12) of C4−/− mice had
measurable infectious WNV in the spinal cord (P ≤ 0.03).
Overall, all complement-deficient mice had significantly
higher peak spinal cord viral burdens by day 10 after infection
compared with wild-type mice (P ≤ 0.03). Additionally,
whereas 100% of complement-deficient mice exhibited
WNV invasion of the spinal cord by day 10 after infection,
only 73% (11 of 15) of wild-type mice had infectious WNV
in the spinal cord at this time point. These results suggest that
the different complement activation pathways modulate the
entry and accumulation of WNV in the spinal cord.
CNS: brain. A slightly different pattern of infection was
observed in the brain, as earlier viral invasion was observed in
all complement-deficient mice (Fig. 4 C). Infectious virus
was not recovered from the brains of wild-type adult mice
until day 6, results that agree with our previous studies (16).
In contrast, infectious virus was detected at day 4 in the brains
of 33% of C4−/− (4 of 12), 18% of C1q−/− (2 of 11), 67% of
fD−/− (8 of 12), and 60% of fB−/− (6 of 10) mice. On average, fD−/− mice had 30-fold higher levels of WNV in the
brain than C1q−/− mice on day 4 after infection (P = 0.02).
1374

Pattern of WNV CNS infection
To evaluate if enhanced CNS WNV infection was the result
of a change in viral tropism, we examined brain and spinal
cord sections for WNV antigen (Fig. 5 and unpublished data).
WNV antigen localized to cells that stained positive for neuronal antigens (unpublished data) throughout the brain and
spinal cord, in agreement with previous studies (16). Intense
antigen staining in complement-deficient mice was observed
in neurons of the cerebellum, brain stem, brain base, and
cortex. Less intense antigen staining in CNS tissues was noted
in wild-type mice, with sporadic infection of similar neuronal populations. Thus, more neurons throughout the brain
and spinal cord were infected at higher levels in the absence
of complement activation compared with wild-type animals.
Virus-specific antibody responses
in complement-deficient mice
Because the production of anti-WNV antibody was depressed
in C3−/− mice (20), we assessed the kinetics of specific antiviral IgM and IgG production in C1q−/−, C4−/−, fD−/−, and
fB−/− mice. Consistent with previous studies (14–16), in
wild-type mice WNV-specific IgM was detected by day 4
after infection (Fig. 6 A), and WNV-specific IgG was detected by day 6 after infection (Fig. 6 B). Near normal development of anti-WNV IgG and IgM was observed in the
absence of alternative pathway activation in fD−/− and fB−/−
mice (P ≥ 0.1). Additionally, in fB−/− mice, we observed no
significant difference in the isotype specificity (Fig. 6 C) or
neutralizing activity of the WNV antibody response (Fig. 6 D).
In contrast, the development of WNV-specific IgG was
COMPLEMENT PATHWAY CONTROL OF WNV INFECTION | Mehlhop and Diamond
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WNV IgM and IgG responses on day 10 after infection
(unpublished data; P = 0.7).

Figure 5. WNV antigen staining in the brain. The brains of wildtype, C1q−/−, C4−/−, and fD−/− mice were harvested on day 10, sectioned,
and stained for WNV. Representative images of the cerebellum, cortex,
and brain stem were determined after staining three to four mice per
group. Bar, 200 μm.

T cell response in C4−/−, C1q−/−, fD−/−, and fB−/− mice
CD8+ T cells are required for clearance of WNV from the
CNS (16, 17). Studies with influenza and lymphocytic choriomeningits virus (LCMV) have found that virus-specific T
cell priming is inhibited in the absence of C3 (4, 27). Because
enhanced WNV accumulation in the CNS is observed in all
complement-deficient mice, we examined how the individual complement pathway deficiencies affected the response of
CD8+ T cells to WNV infection (Fig. 7 A). We evaluated
intracellular IFNγ expression in splenocytes from mock- and
WNV-infected C1q−/−, C4−/−, fD−/−, and fB−/− mice.
By day 8 after infection, there was a 2.5-fold increase in the
total number of splenic CD4+ and CD8+ cells that expressed
IFNγ in both wild-type (P = 0.0007) and C1q−/− mice
(P = 0.03). This increase in IFNγ expression was not
observed in CD4+ or CD8+ splenocytes from WNV-infected
C4−/−, fD−/−, or fB−/− mice. Thus, our data suggests that C4
and the alternative pathway of complement activation both are
required for full T cell responsiveness after WNV infection.

delayed in C1q−/− and C4−/− mice, with three- to fourfold
reduced titers on day 8 after infection, respectively (P ≤
0.0003). However, this deficit disappeared by day 10, as normal levels of anti-WNV IgG were subsequently observed
(P ≥ 0.5). Throughout the time course the anti-WNV IgM
response was reduced only in the absence of C4 (P ≤ 0.03).
Collectively, our serologic data establish that the IgM response to WNV is C4 dependent, yet C1q, fD, and fB independent, suggesting a possible role for the lectin pathway.
Consistent with this, C1q−/− × fD−/− mice had normal anti-

T cell trafficking to WNV-infected CNS
Trafficking of effector T cells into WNV-infected CNS tissues requires cellular activation and up-regulation of select
chemokine receptors (28). As an independent measure of the
T cell activity, we tested which pathway of complement activation was required for T cell migration into the CNS of
WNV-infected animals. We isolated brain-infiltrating leukocytes on day 9 after infection in wild-type, C4−/−,
C1q−/−, and fB−/− mice and quantified T cells by flow cytometry (Fig. 7 C). We isolated an average of 2.3 ± 0.5 ×
104 CD3+CD4+ T cells and 4.2 ± 0.6 × 104 CD3+CD8+
T cells from the brains (n = 18) of wild-type mice. Consistent with our IFNγ expression data, the numbers of infiltrating CD4+ and CD8+ T cells were reduced significantly in

Figure 6. Humoral responses against WNV. Serum samples from
wild-type, C1q−/−, C4−/−, fD−/−, and fB−/− mice were collected at the
indicated time points. Titers of specific IgM (A) and IgG (B) against
WNV were calculated after incubating serum samples with absorbed
control or WNV E proteins. The isotype of WNV-specific IgG responses
(C) was analyzed on day 8 after infection. Neutralizing activity (D) of

serum samples from wild-type and fB−/− mice on day 8 after infection
was determined by a flow cytometry–based neutralization assay. Data
are an average of at least three independent experiments performed
in duplicate and reflect 5–10 mice per group. Asterisks indicate time
points at which differences are statistically significant compared with
wild type (P < 0.05).

JEM VOL. 203, May 15, 2006

1375

Figure 7. T cell activation and trafficking after WNV infection.
(A) Mock or WNV-infected splenocytes from wild-type, C1q−/−, C4−/−,
fD−/−, and fB−/− mice on day 8 were harvested and stimulated ex vivo.
Cells were stained for CD4 or CD8 and intracellular IFNγ and analyzed by
flow cytometry. Data are an average of at least three independent experiments and reflect 6–10 mice per group. Asterisks indicate differences
from mock infected that are statistically significant (*P < 0.05; **P <
0.005). (B) Representative flow cytometry profiles showing intracellular
IFNγ staining of splenic CD8+ T cells after WNV infection in wild-type or
complement-deficient mice. The percentage of double-positive cells is
indicated in the top right corner. (C) Brains were harvested from WNV-

infected wild-type, C1q−/−, C4−/−, and fB−/− mice on day 9. Leukocytes
were isolated by percoll gradient centrifugation and double-stained for
CD3 and CD4 or CD8. The total number of brain infiltrating CD4+ or CD8+
T cells was determined by multiplying the total number of leukocytes
from three pooled brains by the percentage of double-positive cells as
measured by flow cytometry. Data are an average of at least three independent experiments and reflect at least five groups of three mice. Asterisks indicate differences from wild type that are statistically significant
(*P < 0.05; **P < 0.005). (D) Representative flow cytometry profiles
showing CD3+CD8+ T cells in the brain after WNV infection in wild-type
or complement-deficient mice.

the absence of either fB or C4 (n ≥ 12, P ≤ 0.04). No difference in CNS T cell migration was observed in the absence
of C1q in either the CD4+ or CD8+ compartment (n = 15,
P ≥ 0.3). Collectively, our data suggests that the lectin and
alternative pathways of complement activation are required
for normal T cell responsiveness and CNS trafficking after
WNV infection.

yet near normal anti-WNV antibody profiles. Deficiencies in
classical and lectin pathway activation were associated with
decreased splenic infection and significant deficits in both B
and T cell responses against WNV. A deficiency in the classical pathway alone was associated with markedly decreased
splenic infection, yet normal T cell responses and near normal antibody responses. Importantly, not all defects in the
complement system predispose mice to enhanced WNV susceptibility, as mice lacking the C5aR exhibited no increase in
mortality after infection. This latter result was not unexpected
as C5aR activity primarily modulates granulocyte responses,
a cell type that has not been implicated in the pathogenesis or
immune response to WNV infection (29).

DISCUSSION
In this study, we report that different pathways of complement activation can exert independent protective effects in
response to viral infection (Table I). WNV infection activates
the complement system in vivo, and all three complement
activation pathways are required for protection against WNV.
However, differences in priming of adaptive immune responses to WNV were observed in mice lacking individual
components of all three pathways of complement activation.
Deficiencies in the alternative pathway were associated with
slightly delayed splenic clearance, blunted T cell responses,
1376

All pathways of complement activation are required
to control WNV infection
Although clinical studies have suggested that increased complement activation may be associated with more severe forms
of infection with two related viruses of the Flaviviridae family,
COMPLEMENT PATHWAY CONTROL OF WNV INFECTION | Mehlhop and Diamond
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Table I. Summary of phenotypes observed during WNV infection of complement-deficient mice
WT
C4−/−
C1q−/−
fB−/−
fD−/−
C1q × fD−/−

Viremia

Spleen

CNS

IgM

IgG

T cell activity

Survival

+
D4 ++
+
+
+
ND

+
−
None
D6 ++
D6 ++
ND

+
++
++
++
++
ND

+
−
+
+
+
D10 +

+
D8 −
D8 −
+
+
D10 +

+
−
+
−
ND
ND

65%
0%
17%
4%
26%
10%

Viremia, infectious burden in the spleen and CNS, virus-specific IgM and IgG responses, and T cell activity after WNV infection of wild-type, C4−/−, C1q−/−, fB−/−, fD−/−, and
C1q × fD−/− mice are summarized above. Differences from WNV infection in wild-type mice (+) at specific days after infection are indicated. Comparative levels are
indicated by – (low), + (normal), or ++ (high). ND indicates experiments were not performed.

dengue virus (21) and hepatitis C virus (30), C3 was essential
for controlling WNV infection (20). Although the studies in
C3−/− mice were consistent with models of complementdependent control of other viral infections including HSV,
influenza, and LCMV (2–4, 31, 32), no investigation had systematically addressed how the different activation pathways
coordinate protection. Our experiments demonstrate that all
complement activation pathways are required for control of
severe WNV disease. The virologic experiments suggest that
complement limits viral spread and facilitates clearance of
WNV within the CNS. As many complement proteins are
constitutively expressed within the CNS (33) and up-regulated
after infection with other neurotropic viruses (34–36), complement activation in the CNS could be critical for destruction
of viral particles or virus-infected neuronal cells. Alternatively,
the defects observed in priming adaptive immune responses to
WNV in complement-deficient mice (see below) may result in
earlier spread and/or decreased clearance.
Most complement-deficient mice had near wild-type
levels of viral RNA in serum throughout the time course,
suggesting that the dominant antiviral role of complement
activation may not be direct virolysis. Because IgM fixes
complement by the classical pathway and WNV particles can
be neutralized efficiently in vitro by exogenous rabbit complement (20), we anticipated increased viremia in C1q−/−
and C4−/− mice. However, we only observed a transient increase in viremia in C4−/− mice, which may be secondary to
depressed levels of antiviral IgM in these mice. Viral clearance from serum is known to correlate with the induction of
WNV-specific IgM at days 4 and 6 after infection (15). The
relatively low viral neutralizing activity of serum complement in mice may be caused by the reduced function of the
mouse classical pathway C5 convertase (37, 38). Our prior in
vivo experiments support this, as antibody-mediated protection from WNV disease was not significantly attenuated in
C1q−/− or C4−/− mice (39).
Although the magnitude and kinetics of viremia were
roughly equivalent, earlier CNS viral invasion was observed
in all complement-deficient mice. This early CNS seeding
was most consistently observed in mice lacking fB or fD. Although the mechanism remains unclear, alternative pathway
activation during the initial phases of infection could induce
JEM VOL. 203, May 15, 2006

inflammatory mediators that facilitate viral blood-brain barrier
crossing. TNF-α generation in peripheral lymphoid tissues
has been suggested to modulate blood-brain barrier permeability and WNV neuroinvasion (40). Notably, genetic disruption or antibody blockade of alternative pathway activation or
CR3 function significantly inhibited TNF-α secretion from
human or murine leukocytes after exposure to group B Streptococcus (41). Experiments that examine the relationship between CNS viral entry and cytokine profiles after WNV
infection in complement-sufficient and -deficient mice may
elucidate the molecular basis for this stage in pathogenesis.
Classical pathway activation facilitates secondary lymphoid
organ WNV infection
A surprising result was the requirement of C1q and C4 for
normal levels of WNV infection in the spleen and draining
lymph node. In the absence of C1q, infectious virus was not
detected in the spleen, and 100,000-fold less WNV RNA
was measured on day 6 after infection. Additionally, WNV
infection of the draining inguinal lymph nodes was reduced
in the absence of C1q beginning on day 3 after infection. In
the absence of C4, fewer spleen samples contained less infectious virus than those of wild-type animals, and less WNV
RNA was detected in the spleen and draining inguinal lymph
node. At first glance, this observation appears consistent with
earlier in vitro studies that showed complement and antiviral
IgM enhanced WNV infection in macrophages (42, 43). Although these studies suggested that IgM-dependent fixation
of C3 split products (e.g., C3b, C3dg, or iC3b) on WNV
enhanced infection, our prior studies with secreted IgM−/−
or C3−/− mice showed normal WNV splenic infection (15,
20). Based on this, we speculate that C1q directly or indirectly interacts with WNV to facilitate splenic infection.
Direct C1q interaction with viral glycoproteins has been
observed for HIV-1, human T cell lymphotropic virus-1,
and Moloney murine leukemia virus (6), and C1q-dependent enhancement of infection has been demonstrated in
vitro for both HIV-1 and Ebola viruses (44, 45). Our data
clearly establishes that WNV infection in the spleen does not
significantly contribute to viremia or CNS seeding. Somewhat paradoxically, decreased productive splenic infection
did not dramatically alter the induction of primary antiviral B
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and T cell immune responses to WNV. This apparently contrasts with studies which show that follicular localization in
the spleen is complement dependent and required for the
development of antibody responses to soluble antigen (46)
and vesicular stomatitis virus (2). For WNV, we hypothesize
that T and B cell priming may occur in other secondary
lymphoid tissues. Alternatively, despite an absence of productive viral infection in the spleen, sufficient complementdependent antigen trapping occurs for antigen presentation
and priming of antiviral adaptive immune responses.
Complement activation pathways and the humoral response
Combined with previous work, our current experiments indicate that the development of a protective anti-WNV antibody
response, in part, requires C3, C4, and CR1/2 (20). Because
near normal anti-WNV antibody responses were observed in
fB−/− or fD−/− mice, activation of the alternative pathway is
not required for priming the antibody response against WNV.
Our results are consistent with studies which demonstrate that
fB−/− mice exhibit normal B cell priming to T cell–independent and T cell–dependent antigens (47). We observed a transient delay in the development of antiviral IgG but not IgM in
the absence of C1q, consistent with previous reports of defects
in primary T cell–dependent IgG but not IgM responses in
C1q−/− mice (46). Our data suggests the contribution of the
classical pathway to anti-WNV antibody priming is relatively
minor and could be secondary to the defect observed in splenic
infection. The most severe defect in anti-WNV antibody development was observed in the absence of C4, where IgM responses were blunted and IgG responses were delayed. Since
the C1q−/− mice exhibited normal IgM responses, the C4dependent lectin pathway could play an important role in
priming the antiviral IgM against WNV. Although no study
has directly evaluated the contribution of the lectin pathway
to antiviral antibody responses, this idea is consistent with
work on HSV in which both the primary and memory antiviral humoral responses were blunted in C4−/− mice (3, 48).
Defects in MBL function and lectin pathway activation have
been suggested to predispose individuals to HIV-1 (49), HSV2 (7), severe acute respiratory syndrome (50), and chronic
hepatitis B infection (51). We speculate that the lectin pathway may have an essential role in the priming of humoral
responses against some pathogens.
Complement activation pathways and T cell activation
An emerging literature has suggested an essential role for
complement in priming antiviral T cell immunity. T cell responses to influenza and LCMV require C3 activation (4,
27), possibly by enhancing antigen uptake and presentation
or T cell trafficking to infected organs. Efficient CD8+ CTL
responses are critical for development of WNV immunity
(16, 17), and complement-deficient mice with the greatest
mortality (i.e., C4−/− and fB−/−) had associated T cell activation and trafficking deficits. Because previous studies with
soluble antigens suggested that C1q-mediated immune complex trapping contributed to T cell priming (46, 52), we
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expected C1q−/− mice to have T cell deficits; however, this
was not observed. We speculate that WNV antigen uptake
and presentation may be reduced in the absence of lectin
pathway activity and/or C4b deposition. Lectin pathway recognition induces opsonization of influenza virus, HSV-2, and
HIV-1 (53), and C4b deposition and CR1 binding can activate and enhance antigen presentation in human cells (54).
Nonetheless, the defects in antiviral T cell responses in C4−/−
mice could be indirect and attributed to the depressed antiWNV IgM responses and decreased immune complex clearance. Although more experiments are necessary to identify
the exact mechanism, our study is novel as it describes a role
for C4 in T cell function after viral infection.
We also observed a requirement for the alternative pathway in the development of T cell responses after WNV infection. Because others have demonstrated an 80% reduction
in classical pathway-dependent membrane attack complex
formation in the absence of alternative pathway activity (55,
56), WNV antigen presentation may be reduced in the absence of fB because of a failure to amplify classical and/or
lectin pathway-initiated responses. This may attenuate C3bdirected targeting, uptake, and presentation of WNV in lymphoid tissues (2, 4, 27). Alternatively, C3b engagement of
CR3 may promote an appropriate cytokine environment for
antiviral T cell priming: production of IFNγ and IL-12 were
reduced by treatment of human monocytes with CR3 blocking antibodies or natural CR3 ligands (57).
Complement activation plays a critical role in innate recognition and neutralization of pathogens in vivo (3, 4, 58).
Our study expands the current knowledge of the in vivo
mechanisms of complement-mediated antiviral immunity,
and in particular suggests that activation of complement by
distinct pathways may control pathogens by triggering different effector arms of antiviral immunity. A limitation of our
study is that it does not address the precise mechanism by
which the three complement activation pathways stimulate
different adaptive immune responses; the differences could be
because of quantitative or qualitative variation in the generation of C3 or C5 activation fragments. Regardless, a fully
functional complement cascade is clearly important for controlling and clearing WNV given that antibody and CD8+
T cells both are essential for protection (14, 16, 17). It is intriguing to consider that severe WNV infection in humans,
which occurs infrequently (1/150), could be more common in patients with dysfunctional complement responses.
Although complete deficiencies of complement proteins are
rare, heterozygous deficiencies of C4 and MBL are common
(59) and have been associated with an increased risk of viral
diseases (30, 49, 51, 60). As therapies against WNV become
available, it will be important to target high-risk populations.
Depressed levels of complement proteins or reduced complement activity could explain why some seemingly healthy patients develop severe disease after WNV infection. Genetic
studies that evaluate the risk factors of neuroinvasive WNV
infection in humans should include an analysis of common
complement gene allelic polymorphisms.
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MATERIALS AND METHODS
Viruses and cells. The WNV strain 3000.0259 was isolated in New York
in 2000 and used for all studies (61). All mouse experiments used a low passage stock (P = 2) that was propagated once in C6/36 Aedes albopictus cells.
Mice. C4−/− (62), C1q−/− (63), fD−/− (24), C1q × fD−/−, fB−/− (47), and
C5aR−/− (64) mice on a pure C57BL/6 (H-2b) background and were obtained from colleagues (C. Gerard, Harvard Medical School, Boston, MA;
M. Botto, Imperial College, London, UK; M. Carroll, Harvard Medical
School, Boston, MA; G. Stahl, Harvard Medical School, Boston, MA; and
H. Molina, Washington University School of Medicine). The congenic
wild-type C57BL/6 control mice were purchased commercially (Jackson
Laboratories). All mice were housed in the pathogen-free BSL3 mouse facility at Washington University School of Medicine. Studies were performed
in compliance with the guidelines of the Washington University School of
Medicine Animal Safety Committee. 8–12-wk-old mice were inoculated
subcutaneously via footpad injection with 102 PFUs diluted in Hanks balanced salt solution and 1% heat inactivated FBS.
Complement hemolysis assays. Levels of functional mouse C4 were
determined by an erythrocyte hemolysis assay as previously described (23).
In brief, sheep erythrocytes (Colorado Serum Co.) were coated with rabbit
anti–sheep erythrocyte IgG (Rockland Immunochemical) at 37°C for 30 min.
After extensive washing, antibody-coated sheep erythrocytes (5 × 106) were
mixed with C4-depleted guinea pig serum (Complement Technologies,
Inc.) and serial dilutions of mouse serum from naive or WNV-infected
C57BL/6 mice. Reactions were incubated at 37°C for 1 h and stopped by
the addition of 1 vol of PBS at 0°C. Erythrocytes were pelleted, supernatants
were removed, and lysis was measured by using a 96-well plate reader at an
OD405. Levels of C3 were determined as above using C3-depleted normal
human serum (Complement Technologies). The 50% value of hemolytic
complement activity (CH50) was determined as described previously (65).
C3 Western blotting. Complement activation was assessed by Western
blot as previously described (24). Serum samples were collected from naive
or WNV-infected C57BL/6 mice on day 2 after infection, diluted in PBS,
boiled in SDS reducing sample buffer, and subjected to SDS PAGE using a
4–20% gradient gel. After transfer to a PVDF membrane, C3 and its cleavage
products were detected with goat anti–mouse C3 IgG (MP Biomedicals)
followed by horseradish peroxidase–conjugated donkey anti–goat IgG
F(ab)′2 (Jackson ImmunoResearch). C3 bands were visualized using the
ECL Plus chemiluminescent substrate system (BD Biosciences).
Quantification of viral burden. For analysis of viral burden, organs were
recovered at days 2, 4, 6, 8, and 10 postinfection after cardiac perfusion with
10 ml of PBS. Tissues were weighed, homogenized using a Bead-beater
apparatus, and titrated for WNV by plaque assay on BHK21-15 cells as
described previously (14). Serum was obtained from whole blood by phlebotomy of the axillary vein immediately before sacrifice. Viral RNA was
prepared from serum by using a Qia-Amp viral RNA recovery kit (Qiagen)
and quantified by real-time fluorogenic RT-PCR on an ABI 7000 sequence
detection system (Applied Biosystems) using primers and probes corresponding to a segment of the E gene as described previously (25). Viral RNA
was extracted from lymph node and spleen tissue homogenates using
the RNeasy isolation kit (Qiagen) and quantified by fluorogenic RT-PCR
as described above. Values were normalized to the level of 18S RNA as
determined by fluorogenic RT-PCR with a commercially available kit
(Applied Biosystems).
Serologic analysis. WNV-specific IgM and IgG levels were determined
by an envelope (E) protein–specific ELISA, as described previously (14). In
brief, a soluble WNV E-protein with a COOH-terminal hexa-histidine
(His6) tag was purified from baculovirus-infected Hi5 insect cells by nickelaffinity chromatography (39) and used to coat Maxi-Sorp microtiter plates
(Nalgene Nunc) overnight at 4°C. After blocking with PBS 1% BSA, 3%
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horse serum, 0.05% Tween-20, and 0.025% NaN3, plates were incubated
with fourfold serial dilutions of heat-inactivated serum samples overnight
at 4°C. Plates were washed, incubated with biotin-conjugated goat anti–
mouse IgM, IgG, IgG1, IgG2a, IgG2c, or IgG3 (Southern Biotech), followed
by strepatavidin-HRP (Invitrogen), and developed with tetramethylbenzidine substrate (Dako). The OD450 was determined, and the adjusted OD
was determined by subtracting the OD450 value for each sample on blocked
control wells. Titers represent the serum dilution yielding an adjusted
OD450 value equivalent to three standard deviations above the background
of the assay.
The neutralizing activity of the WNV-specific antibody response was
determined using a previously described high-throughput flow cytometry–
based neutralization assay with WNV virus-like particles that express a reporter gene (green fluorescent protein [GFP]) (66). WNV virus-like particles
were incubated with serial dilutions of heat-inactivated serum samples before
incubation with permissive Raji cells expressing DC-SIGN-R (67). 2 d
later, cells were fixed in 1% paraformaldehyde, analyzed by flow cytometry
for GFP expression, and the titer of 50% inhibition (EC50) was determined
using GraphPad Prism software.
Immunohistochemistry. Brain and spinal cord were harvested from
infected mice on day 10 postinfection after perfusion with 20 ml of PBS.
Tissues were fixed in 4% paraformaldehyde in PBS for 24 h at 4°C, then
embedded in paraffin, sectioned, and stained for WNV infection using mAbs
(E18, E22, and E33) against the WNV E protein (18), after an antigen retrieval step (Dako Cytomation). Staining was detected after incubation with
streptavidin-conjugated horseradish peroxidase and development with diaminobenzidine. Slides were counterstained with hematoxylin to facilitate
visualization of tissue histology.
Intracellular IFN-𝛄 staining. Intracellular IFN-γ staining of wild-type
and complement-deficient splenocytes was performed as described previously (19). In brief, at day 8 after infection, splenocytes were harvested from
wild-type and C1q−/−, fD−/−, fB−/−, or C4−/− mice. Erythrocytes were
lysed with ACK lysis buffer (0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM
Na2EDTA) and splenocytes were counted. In a 96-well plate, 106 splenocytes were stimulated with 50 ng/ml PMA (Sigma-Aldrich) and 1 μM Ionomycin (Sigma-Aldrich) in the presence of Golgi plug (BD PharMingen) for
4 h at 37°C. Cells were harvested and stained with either FITC-conjugated
anti-CD4 (L3T4) or anti-CD8α (Ly-2) antibody (BD PharMingen). Cells
were then washed and fixed in 4% paraformaldehyde, permeabilized with
0.5% saponin, and stained with AlexaFluor 647–conjugated rat anti–mouse
IFN-γ antibody or rat IgG1 isotype control (BD PharMingen), and analyzed
by flow cytometry. The total numbers of IFNγ-expressing CD8+ cells was
determined by multiplying the percentage of IFNγ+ CD8+ cells by the total
numbers of splenocytes harvested.
Brain T cell isolation. Brain infiltrating CD4+ and CD8+ T cells were
isolated and quantified as previously described (68). Complement-deficient
and wild-type mice were anaesthetized and perfused with 20 ml of PBS on
day 9 after infection with 102 PFU of WNV. Individual brains were harvested into RPMI supplemented with 5% FBS and homogenized by pressing
through a 70-μm mesh tissue strainer (BD Biosciences). The cell homogenates were centrifuged, and the cell pellets were resuspended in RPMI with
5% FBS and overlaid on a 70–30% isotonic percoll (Pharmacia) step gradient. The gradients were centrifuged (800 g for 25 min at 25°C), and the leukocytes were collected from between the 70 and 30% interface. Leukocytes
from three brains were pooled, washed twice, and stained for CD4+ or
CD8+ T cells with anti-CD3 (17A2) and anti-CD8α (Ly-2) or anti-CD4
(L3T4) antibodies (BD PharMingen) in the presence of 5% goat serum after
Fc block (2.4G2; BD PharMingen). After washing, cells were fixed with 1%
paraformaldehyde in PBS and analyzed by FACscan (Becton Dickinson)
with CellQuest software. The total numbers of CD4+ or CD8+ T cells from
each brain were determined by multiplying the percentage of CD3+CD4+
or CD3+CD8+ cells by the total numbers of leukocytes harvested.
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Data analysis. For survival analysis, Kaplan-Meier survival curves were
plotted using Prism software (GraphPad) and analyzed by the log rank test.
Statistical significance of complement levels, survival time, viral burdens,
antiviral antibody titers, and total number of activated T cells were analyzed
by an unpaired t test or Mann-Whitney test.
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